Abstract
This report updates the latest procurement forecasts for artemisinin-combination therapies (ACTs) and artemisinin in 2012-2013. It is produced by the ACT forecasting consortium which includes The Boston Consulting Group, the Clinton Health Access Initiative, and Fundacion Zaragoza Logistics Center (MIT-Zaragoza). Funded and coordinated by UNITAID, the project brings together forecasters originally working under the Roll Back Malaria (RBM) umbrella in an effort to produce a single ACT forecast for use by the malaria community. The consortium is overseen by a Steering Committee that includes representatives from the Affordable Medicines Facility-malaria (AMFm), the Global Fund, Medicines for Malaria Venture (MMV), Roll Back Malaria (RBM), UNITAID, and the World Health Organization (WHO).
This is the sixth in a series of consortium forecasts that will be produced through early 2013. Each quarter, the forecasts are revised based on new information about ACT funding and market dynamics. Since this Q3 forecast update is only modestly different from the Q1 and Q2 forecast, the new figures are summarized in this brief report, and we refer readers to our full Q1 report for a detailed description of the project context and methods.
